SASandra R. Arnold

Sandra R. Arnold

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandra R. Arnold has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Histoplasmosis in children: emerging insights and evolving guidelines

    by Kate Shapiro, Sandra R. Arnold

    Purpose of review: This review provides an update on the epidemiology, risk factors, clinical presentation, diagnosis, and management recommendations incorporating recommendations from recent publications including the Infectious Disease Society of America guidelines for the management of pulmonary and disseminated histoplasmosis. Recent findings: Updates to the epidemiology of histoplasmosis indicate a broader geographic range than historically defined. Updated guidelines do not recommend routine treatment for asymptomatic, mild and moderate pulmonary histoplasmosis although itraconazole can be offered for immunocompromised children or for prolonged or worsening symptoms. Liposomal amphotericin B is recommended as initial treatment for severe histoplasmosis syndromes (severe pulmonary and disseminated histoplasmosis). Fibrosing mediastinitis, a late complication of histoplasmosis is treated with stenting of vessels and bronchi. Recent studies demonstrate that rituximab (anti-CD20 monoclonal antibody) may stop progression or lead to regression of progressive fibrosis. Summary: Histoplasmosis has manifold manifestations, many of which are self-limited and do not require treatment. Severe histoplasmosis and its complications should be treated with liposomal amphotericin B followed by itraconazole. Clinical trials are needed to assess the efficacy of rituximab for the treatment of fibrosing mediastinitis.

  • Audiological Outcomes of Cytomegalovirus Saliva PCR‐Positive Newborns in Support of Universal Screening

    by Celine Richard, Leyn Shakhtour, Nina Gallo, Rebecca Smith, Charles B. MacDonald, Ramona Gentry, Hayley Scheerer, Sandra R. Arnold, Maria A. Carrillo‐Marquez

    Objective: This study aims to describe the audiological outcomes of cytomegalovirus (CMV)‐positive newborns detected through universal screening. Study Design: Retrospective cohort. Setting: Three nurseries and a neonatal intensive care unit in Memphis, Tennessee. Methods: Data were analyzed from patients screened for congenital CMV (cCMV) by saliva polymerase chain reaction from March 2016 to May 2024. Newborns were classified based on symptoms at birth. Results: Among 247 CMV‐positive newborns (134 males, 54.2%), 77 (31.17%) were symptomatic. Among these, 16 were diagnosed with sensorineural hearing loss (SNHL): 12 bilateral SNHL (BHL), 4 with unilateral SNHL (UNHL). Three symptomatic patients developed late‐onset UNHL. Four of the asymptomatic newborns developed UNHL, and one BHL, within the first year of life. Fifty‐eight patients received valganciclovir. Among the patients who eventually developed SNHL, 5/10 treated experienced worsening or lack of improvement; 10/14 untreated cases showed hearing deterioration or did not improve, and 2/14 remained stable. Patients with SNHL had higher rates of microcephaly and intracranial calcifications compared to those with normal hearing but showed no differences in urine CMV viral load at birth. In the current cohort, nine patients have cochlear implants (seven bilateral, one unilateral) and four have hearing aids (three bilateral, one unilateral). Social vulnerability was associated with fewer follow‐ups in patients with SNHL. Conclusion: This study underscores the profound impact of cCMV infection on hearing outcomes, even when asymptomatic at birth. It reinforces the importance of universal cCMV screening programs to identify infants at risk for SNHL. It also highlights the impact of social determinants of health on long‐term follow‐up.


  • Open Access

    1307. Vaso-occlusive Crisis is Associated with Subsequent Osteomyelitis in Pediatric Sickle Cell Disease

    by Kate Shapiro, Joshua Wolf, Rohith Jesudas, Jeffrey C Winer, Sandra Arnold

    Children with sickle cell disease (SCD) commonly develop microvascular infarcts of bone known as vaso-occlusive crisis (VOC) and are also at high risk of osteomyelitis (OM). VOC and OM can be challenging to distinguish due to overlapping clinical features. VOC might predispose to OM, or an initial misdiagnosis of OM as VOC might lead to delayed diagnosis of OM. This study aimed to test whether VOC was associated with subsequent development of OM in children with SCD. A retrospective Pediatric Health Information System (PHIS) database study (2010-2021) was performed. ICD-code data related to common diagnoses in pediatric patients with SCD were extracted. The rate of VOC within 30 and 180 days preceding episodes of OM was compared to the rate preceding acute chest syndrome (ACS), another common diagnosis in children with SCD but unlikely to be anatomically related to OM. Odds ratios (OR) were used to evaluate the association between these diagnoses. Of 22,818 PHIS participants with SCD, 13,699; 450; and 7,327 had ≥ 1 episode of VOC, OM and ACS, respectively. The distribution of OM diagnoses was similar across pre-specified age groups (0-4, 5-12, and 13-18 years). The odds ratio of VOC preceding a diagnosis of OM vs. ACS was 2.15 within 30 days (95% CI: 1.82-2.54; p= 3.68 x 10-18), and within 180 days was 1.39 (95% CI: 1.20-1.62; p=2.04 x 10-5). VOC was significantly more common in the days preceding a diagnosis of OM than of ACS. The strength of association was stronger within 30 days prior to OM than 180 days. These results suggest possible misdiagnosis of OM since VOC might delay OM diagnosis in some cases, that recurrent VOC might be misdiagnosed as OM, or that VOC can directly contribute to risk of OM in some cases. Limitations of this study include possible incomplete adjustment for unmeasured variables which could confound the analysis. More research is needed to confirm and evaluate the mechanism behind this association. Understanding the relationship could lead to improved screening and treatment of both VOC and OM. Joshua Wolf, MBBS, PhD, Karius Inc.: Grant/Research Support|Merck Inc.: Participation in industry-sponsored research Sandra Arnold, MD, Contrafect: Grant/Research Support|Enanta: Grant/Research Support|Moderna: Grant/Research Support|Pfizer: Grant/Research Support

  • Association of Radiology Findings with Etiology of Community Acquired Pneumonia among Children

    by Sandra R. Arnold, Seema Jain, David Dansie, Herman Kan, Derek J. Williams, Krow Ampofo, Evan J. Anderson, Carlos G. Grijalva, Anna M. Bramley, Andrew T. Pavia, et al.


  • Open Access

    A Culture Change: Impact of a Pediatric Antimicrobial Stewardship Program Based on Guideline Implementation and Prospective Audit with Feedback

    by Bindiya Bagga, Jeremy S. Stultz, Sandra Arnold, Kelley R. Lee

    Reports analyzing the impact of pediatric antimicrobial stewardship programs (ASP) over long periods of time are lacking. We thus report our ASP experience in a pediatric tertiary referral center over a long-term period from 2011 to 2018. Our ASP was implemented in 2011. The program was based primarily on guideline development with key stakeholders, engaging and educating providers, followed by prospective audit with feedback (PAF). Monitored antibiotics included meropenem, piperacillin–tazobactam, and cefepime, followed by the addition of ceftriaxone, ceftazidime, cefotaxime, ciprofloxacin, levofloxacin, linezolid, and vancomycin at various time points. Specifically, the program did not implemented the core strategy of formulary restriction with prior authorization. Process- and outcome-related ASP measures were analyzed. We saw a 32% decrease in overall antibiotic utilization, a 51% decrease in the utilization of antibiotics undergoing PAF, and a 72% reduction in the use of broad-spectrum antibiotics such as meropenem. There was a concomitant increase in organism susceptibility and a reduction in yearly drug purchasing costs of over USD 560,000 from baseline without changes in sepsis-related mortality. Our study highlights that a pediatric ASP based primarily on the principles of guideline development and PAF can improve antibiotic utilization and institutional bacterial susceptibilities without a detrimental impact on patient outcomes by changing the culture of antimicrobial utilization within the institution.


  • Lemierre’s Syndrome Due to the Zoonotic Anaerobe Bacteroides pyogenes: Case Report and Literature Review

    by Kathryn P Goggin, Nicholas Beckmann, Kristen Bettin, Maria Carrillo-Marquez, Joshua Wood, Sandra R Arnold

    Although Fusobacterium necrophorum is well described as an emerging pathogen of acute mastoiditis in young children, infection with other anaerobes can lead to similar severe sequelae including intracranial and extracranial suppurative thrombophlebitis and sepsis. We describe a patient whose unremarkable exposure history assumed increased significance upon obtaining the results of 16S next generation sequencing from a surgical specimen. The novel pathogen Bacteroides pyogenes is reviewed herein.


  • Mediastinal Lymphadenopathy in Children With Histoplasmosis

    by Jessica K. Staszak, Polina Zmijewski, Sandra Arnold, Bindiya Bagga, Regan F. Williams


  • Syphilis in Children

    by Sarah Heston, Sandra Arnold


  • Open Access

    Relationship Between Body Mass Index and Outcomes Among Hospitalized Patients With Community-Acquired Pneumonia

    by Anna M. Bramley, Carrie Reed, Lyn Finelli, Wesley H. Self, Krow Ampofo, Sandra R. Arnold, Derek J. Williams, Carlos G. Grijalva, Evan J. Anderson, Chris Stockmann, et al.

    The effect of body mass index (BMI) on community-acquired pneumonia (CAP) severity is unclear. We investigated the relationship between BMI and CAP outcomes (hospital length of stay [LOS], intensive care unit [ICU] admission, and invasive mechanical ventilation) in hospitalized CAP patients from the Centers for Disease Control and Prevention Etiology of Pneumonia in the Community (EPIC) study, adjusting for age, demographics, underlying conditions, and smoking status (adults only). Compared with normal-weight children, odds of ICU admission were higher in children who were overweight (adjusted odds ratio [aOR], 1.7; 95% confidence interval [CI], 1.1–2.8) or obese (aOR, 2.1; 95% CI, 1.4–3.2), and odds of mechanical ventilation were higher in children with obesity (aOR, 2.7; 95% CI, 1.3–5.6). When stratified by asthma (presence/absence), these findings remained significant only in children with asthma. Compared with normal-weight adults, odds of LOS >3 days were higher in adults who were underweight (aOR, 1.6; 95% CI, 1.1–2.4), and odds of mechanical ventilation were lowest in adults who were overweight (aOR, 0.5; 95% CI, .3–.9). Children who were overweight or obese, particularly those with asthma, had higher odds of ICU admission or mechanical ventilation. In contrast, adults who were underweight had longer LOS. These results underscore the complex relationship between BMI and CAP outcomes.


  • Community-Acquired Pneumonia Hospitalization among Children with Neurologic Disorders

    by Alexander J. Millman, Lyn Finelli, Anna M. Bramley, Georgina Peacock, Derek J. Williams, Sandra R. Arnold, Carlos G. Grijalva, Evan J. Anderson, Jonathan A. McCullers, Krow Ampofo, et al.